Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
The Motley Fool
AUGUST 11, 2024
Less than three years after raising $510 million in its initial public offering, Exscientia (NASDAQ: EXAI) has thrown in the towel and agreed to merge with Recursion Pharmaceuticals (NASDAQ: RXRX) , another AI-driven drug developer. billion as of June 30, 2024. Consider when Nvidia made this list on April 15, 2005.
Let's personalize your content